Analysis Item |
English Abbreviation |
Clinical Application |
Sample Type |
Linearity Range |
Cardiac Troponin I |
cTn I |
Myocardial infarction |
Whole blood, serum and plasma |
0.2~50ng/mL |
N-Terminal Pro-brain Natriuretic Peptide |
NT-proBNP |
Cardiac failure |
Whole blood, serum and plasma |
200~30000pg/mL |
Brain Natriuretic Peptide |
BNP |
Cardiac failure |
Whole blood, serum and plasma |
20~5000pg/mL |
Cardiac Troponin I/Myohemoglobin/Creatine Kinase Isoenzyme |
cTnI/Myo/CK-MB |
Myocardial infarction, myocardial damage, and differentiation of cardiogenic dyspnea and pulmonary dyspnea |
Whole blood, serum and plasma |
cTnI:0.2~50ng/mL; Myo:20~500ng/mL; CK-MB:2~100ng/mL |
Heart-type Fatty Acid Binding Protein |
HFABP |
Early markers of acute myocardial infarction and myocardial damage |
Whole blood, serum and plasma |
1~120ng/mL |
D-Dimer |
D-D |
Deep venous thrombosis and pulmonary embolism exclusion diagnosis and thrombolysis effect assessment |
Whole blood and plasma |
0.2~10.0µg/mL |
Human Myeloperoxidase |
MPO |
Acute coronary syndrome and Myocardial infarction |
Whole blood, serum and plasma |
12~1000ng/mL |
Lipoprotein Phospholipase A2 |
Lp-PLA2 |
Atherosclerosis and cardio-cerebrovascular embolism |
Whole blood, serum and plasma |
10~1000ng/mL |
Soluble Growth Stimulating Expression Gene 2 Protein |
ST2 |
Heart failure markers |
Whole blood, serum and plasma |
2~200ng/mL |